With the wide application of nucleos(t)ide analogues (NAs) in antiviral therapy for chronic hepatitis B (CHB), the side effects of NAs after long-term use have attracted more and more attention from clinicians and patients. In recent years, an increasing number of studies have reported muscle injury in CHB patients treated with NAs, and we have gained a deeper understanding of the incidence rate, pathogenesis, and treatment of muscle injury. This article reviews the incidence rate, related factors, clinical manifestations, pathogenesis, management, and prevention and treatment of muscle injury associated with NAs.